Abstract
In this review it is shown that nimesulide, a selective cyclooxigenase-2 (COX-2) inhibitor, is different from other selective COX-2 inhibitors and classical non-steroidal anti-inflammatory drugs (NSAIDs). The anti-inflammatory effect mechanism of nimesulide (inhibition of inflammatory mediators) is similar to other classic NSAIDs, but the protective effect of nimesulide on classic NSAIDinduced ulcers elucidates the difference between nimesulide and these other drugs. It is known that the selective COX-2 inhibitor nimesulide prevents NSAID-induced ulcers, while celecoxib and rofecoxib, which are more selective to COX-2, failed to prevent these ulcers. Nimesulide produces gastro-protective effects via a completely different mechanism. In addition, while selective COX-2 inhibitors increase the risk for cardiovascular diseases, nimesulide does not exert significant cardiotoxicity. This data suggests that gastrointestinal side effects of classic NSAIDs cannot be related to the COX-1 inhibition alone and also suggest that nimesulide is an atypical NSAID, which is different from both non-selective and selective COX-2 inhibitors.
Keywords: Nimesulide, cyclooxygenase, NSAID, chemical structure, side effect, antiulcer effect
Current Medicinal Chemistry
Title: Nimesulide is a Selective COX-2 Inhibitory, Atypical Non-Steroidal Anti-Inflammatory Drug
Volume: 15 Issue: 3
Author(s): H. Suleyman, E. Cadirci, A. Albayrak and Z. Halici
Affiliation:
Keywords: Nimesulide, cyclooxygenase, NSAID, chemical structure, side effect, antiulcer effect
Abstract: In this review it is shown that nimesulide, a selective cyclooxigenase-2 (COX-2) inhibitor, is different from other selective COX-2 inhibitors and classical non-steroidal anti-inflammatory drugs (NSAIDs). The anti-inflammatory effect mechanism of nimesulide (inhibition of inflammatory mediators) is similar to other classic NSAIDs, but the protective effect of nimesulide on classic NSAIDinduced ulcers elucidates the difference between nimesulide and these other drugs. It is known that the selective COX-2 inhibitor nimesulide prevents NSAID-induced ulcers, while celecoxib and rofecoxib, which are more selective to COX-2, failed to prevent these ulcers. Nimesulide produces gastro-protective effects via a completely different mechanism. In addition, while selective COX-2 inhibitors increase the risk for cardiovascular diseases, nimesulide does not exert significant cardiotoxicity. This data suggests that gastrointestinal side effects of classic NSAIDs cannot be related to the COX-1 inhibition alone and also suggest that nimesulide is an atypical NSAID, which is different from both non-selective and selective COX-2 inhibitors.
Export Options
About this article
Cite this article as:
Suleyman H., Cadirci E., Albayrak A. and Halici Z., Nimesulide is a Selective COX-2 Inhibitory, Atypical Non-Steroidal Anti-Inflammatory Drug, Current Medicinal Chemistry 2008; 15 (3) . https://dx.doi.org/10.2174/092986708783497247
DOI https://dx.doi.org/10.2174/092986708783497247 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Drp1 in Ischemic Neuronal Death: An Unusual Suspect
Current Medicinal Chemistry Monoclonal Antibodies Targeting the Epidermal Growth Factor Receptor
Current Drug Targets 2D and 3D-QSAR analysis of pyrazole-thiazolinone derivatives as EGFR kinase inhibitors by CoMFA and CoMSIA
Current Computer-Aided Drug Design Pharmacokinetic Analysis of Taxane Through a Validated Ultra-High Performance Liquid Chromatography-Synapt Mass Spectrometry (UHPLC-MS/MS ESI-Q-TOF) Method
Current Bioactive Compounds Overview of Medicinally Important Diterpenoids Derived from Plastids
Mini-Reviews in Medicinal Chemistry Dietary Phenolic Acids and Flavonoids as Potential Anti-Cancer Agents: Current State of the Art and Future Perspectives
Anti-Cancer Agents in Medicinal Chemistry Editorial (Thematic Issue: New Insights into a Classical Pathway: Key Roles of the Mevalonate Cascade in Different Diseases (Part I))
Current Molecular Pharmacology Preface
Current Radiopharmaceuticals A Review on Exploring Better Safety Prospects in Managing Cancer using Liposomal Combinations of Food Bioactive Compounds and Anticancer Drugs: Combisomes
Current Drug Delivery Experimental Strategies in Autoimmunity: Antagonists of Cytokines and their Receptors, Nanocarriers, Inhibitors of Immunoproteasome, Leukocyte Migration and Protein Kinases
Current Pharmaceutical Design Modulation of Signaling Enhances the Efficacy of the Combination of Satraplatin and Erlotinib
Current Drug Targets Preclinical and Clinical Efficacy of the Bisphosphonate Ibandronate in Cancer Treatment
Current Clinical Pharmacology Xenobiotic-Induced Transcriptional Regulation of Xenobiotic Metabolizing Enzymes of the Cytochrome P450 Superfamily in Human Extrahepatic Tissues
Current Drug Metabolism Drug Delivery Systems and Combination Therapy by Using Vinca Alkaloids
Current Topics in Medicinal Chemistry Growth Factor Signaling and Resistance to Cancer Chemotherapy
Current Topics in Medicinal Chemistry Targeting Telomerase for Cancer Therapy
Current Cancer Therapy Reviews Signaling Transduction Network Mediated by Tumor Suppressor/Susceptibility Genes in NPC
Current Genomics Brain-metastatic Breast Cancer: Clinical Considerations and Pharmacological Approaches
Anti-Cancer Agents in Medicinal Chemistry Targeting the Tumor Proteasome as a Mechanism to Control the Synthesis and Bioactivity of Matrix Macromolecules
Current Molecular Medicine Detection of Cancer Cells on a Chip
Current Topics in Medicinal Chemistry